Apimeds Pharmaceuticals US, Inc (APUS) quarterly balance sheet — complete assets, liabilities & equity history
| Total Current Assets | 13.15M | 13.98M | 9.09M | 10.35M | 259.9K | 13.06K | 36.91K | 73.66K | 157.72K | 422.08K | 922.73K | 6.17K |
| Cash & Short-Term Investments | 2.48M | 3.64M | 6.99M | 8.74M | 250.34K | 3.46K | 26.57K | 63.33K | 147.38K | 410.48K | 751.05K | 6.17K |
| Cash Only | 979.53K | 1.64M | 6.99M | 8.74M | 250.34K | 3.46K | 26.57K | 63.33K | 147.38K | 410.48K | 751.05K | 6.17K |
| Short-Term Investments | 1.5M | 2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 10.67M | 8.05M | 2.1M | 0 | 0 | 9.6K | 10.34K | 10.34K | 10.34K | 11.6K | 0 | 0 |
| Total Non-Current Assets | 128.07M | 150.2M | 163.93K | 197.13K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Property, Plant & Equipment | 228.37K | 239.02K | 34.19K | 13.14K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 149.89M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 127.84M | 75.48K | 129.74K | 184K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 141.22M | 164.18M | 9.25M | 10.55M | 259.9K | 13.06K | 36.91K | 73.66K | 157.72K | 422.08K | 922.73K | 6.17K |
| Asset Turnover | - | - | - | - | - | - | - | - | - | - | - | - |
| Asset Growth % | 54235.12% | 1257338.43% | 24963.09% | 14217.67% | 64.79% | -96.91% | -96% | - | - | 6739.67% | - | - |
| Total Current Liabilities | 14.58M | 10.71M | 1.09M | 809K | 1.77M | 1.02M | 761.4K | 488.17K | 136.48K | 123.31K | 377.07K | 319.78K |
| Accounts Payable | 0 | 918.65K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.6K | 36.88K |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 9.36M | 7.59M | 500K | 500K | 623.62K | 250K | 250K | 100K | 0 | 0 | 315K | 260K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.58M | 1.62M | 18.25K | 182.66K | 287.05K | 180.55K | 77K | 26K | 0 | 0 | 0 | 0 |
| Current Ratio | 0.90x | 1.31x | 8.34x | 12.79x | 0.15x | 0.01x | 0.05x | 0.15x | 1.16x | 3.42x | 2.45x | 0.02x |
| Quick Ratio | 0.90x | 1.31x | 8.34x | 12.79x | 0.15x | 0.01x | 0.05x | 0.15x | 1.16x | 3.42x | 2.45x | 0.02x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 118.81K | 129.45K | 0 | 0 | 250K | 346.84K | 321.99K | 299.46K | 285.84K | 266.89K | 400K | 400K |
| Long-Term Debt | 118.81K | 0 | 0 | 0 | 250K | 346.84K | 321.99K | 299.46K | 285.84K | 266.89K | 400K | 400K |
| Capital Lease Obligations | 0 | 129.45K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 14.7M | 10.84M | 1.09M | 809K | 2.02M | 1.37M | 1.08M | 787.63K | 422.32K | 390.2K | 777.07K | 719.78K |
| Total Debt | 9.53M | 7.76M | 500K | 500K | 873.62K | 596.84K | 571.99K | 399.46K | 285.84K | 266.89K | 715K | 660K |
| Net Debt | 8.55M | 6.12M | -6.49M | -8.24M | 623.28K | 593.39K | 545.42K | 336.14K | 138.46K | -143.59K | -36.05K | 653.83K |
| Debt / Equity | 0.08x | 0.05x | 0.06x | 0.05x | - | - | - | - | - | 8.37x | 4.91x | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -39.80x | -4.36x | -281.69x | -114.48x | -9.58x | -7.64x | -9.19x | -19.31x | -10.02x | -41.07x | -12.60x | -7.87x |
| Total Equity | 126.52M | 153.35M | 8.16M | 9.74M | -1.76M | -1.36M | -1.05M | -713.97K | -264.6K | 31.87K | 145.66K | -713.61K |
| Equity Growth % | 7286.26% | 11391.18% | 879.81% | 1463.89% | -565.35% | -4361.31% | -818.45% | - | - | 104.47% | - | - |
| Book Value per Share | 8.16 | 14.09 | 6.49 | 9.39 | -1.52 | -1.07 | -0.82 | -0.56 | -0.21 | 0.03 | 0.11 | -0.56 |
| Total Shareholders' Equity | 126.52M | 153.35M | 8.16M | 9.74M | -1.76M | -1.36M | -1.05M | -713.97K | -264.6K | 31.87K | 145.66K | -713.61K |
| Common Stock | 125.76K | 125.76K | 125.76K | 125.76K | 79.04K | 79.04K | 205.5K | 205.5K | 205.5K | 205.5K | 150K | 100K |
| Retained Earnings | -45.45M | -10.39M | -9.24M | -7.46M | -4.79M | -4.39M | -4.08M | -3.75M | -3.3M | -3M | -2.43M | -2.22M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |